Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)

被引：16

作者：

Maeda, Haruka ^{[1
,2
]}

Saito, Nobuo ^{[3
]}

Igarashi, Ataru ^{[4
,5
]}

Ishida, Masayuki ^{[6
]}

Suami, Kazuya ^{[7
]}

Yagiuchi, Ai ^{[7
]}

Kimura, Yuya ^{[8
]}

Komino, Masaru ^{[8
]}

Arai, Hiromi ^{[8
]}

Morikawa, Toru ^{[9
]}

Motohashi, Iori ^{[10
]}

Miyazawa, Rei ^{[10
]}

Moriyama, Tetsu ^{[11
]}

Kamura, Hiroshi ^{[12
]}

Terada, Mayumi ^{[13
]}

Kuwamitsu, Osamu ^{[14
]}

Hayakawa, Tomoichiro ^{[15
]}

Sando, Eiichiro ^{[16
,17
]}

Ohara, Yasuji ^{[18
]}

Teshigahara, Osamu ^{[19
]}

Suzuki, Motoi ^{[20
]}

Morimoto, Konosuke ^{[1
]}

机构：

[1] Nagasaki Univ, Inst Trop Med, Dept Resp Infect, 1-12-4 Sakamoto, Nagasaki 8528523, Japan

[2] Nagasaki Univ, Dept Clin Trop Med, Grad Sch Biomed Sci, Nagasaki, Japan

[3] Oita Univ, Fac Med, Dept Microbiol, Oita, Japan

[4] Yokohama City Univ, Unit Publ Hlth & Prevent Med, Sch Med, Yokohama, Kanagawa, Japan

[5] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Econ & Outcomes Res, Tokyo, Japan

[6] Chikamori Hosp, Kochi, Japan

[7] Nagoya Ekisaikai Hosp, Nagoya, Aichi, Japan

[8] Saiseikai Kurihashi Hosp, Saitama, Japan

[9] Nara City Hosp, Nara, Japan

[10] Kawasaki Municipal Tama Hosp, Kawasaki, Kanagawa, Japan

[11] Moriyama Mem Hosp, Tokyo, Japan

[12] Loco Clin Nakameguro, Tokyo, Japan

[13] Nijigaoka Hosp, Nagasaki, Japan

[14] Gohongi Clin, Tokyo, Japan

[15] Hayakawa Internal Med Clin, Fukuoka, Japan

[16] Kita Fukushima Med Ctr, Fukushima, Japan

[17] Fukushima Med Univ, Fukushima, Japan

[18] Takagi Hosp, Nagoya, Aichi, Japan

[19] Mizuho St Clin, Nagoya, Aichi, Japan

[20] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan

来源：

CLINICAL INFECTIOUS DISEASES | 2022年 / 75卷 / 11期

关键词：

SARS-CoV-2; COVID-19; vaccine effectiveness; Delta; Japan;

D O I：

10.1093/cid/ciac292

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This multicenter test-negative case-control study showed messenger RNA COVID-19 vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Japan during July-September 2021: 88.7% among people aged 16-64 years and 90.3% among those aged >= 65 years. Background Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. Methods We conducted a multicenter test-negative case-control study in patients aged >= 16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (>= 90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16-64 years was also assessed. Results We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses >= 14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%-93.9%) among patients aged 16-64 years and 90.3% (95% CI, 73.6%-96.4%) among patients aged >= 65 years. Among patients aged 16-64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%-96.6%) within 1-3 months after full vaccination, and 86.4% (95% CI, 56.9%-95.7%) within 4-6 months. Conclusions mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July-September 2021, when the Delta variant was dominant nationwide.

引用

页码：1971 / 1979

页数：9

共 50 条

[31] Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2
Rajasekharan, Sreejith
Milan Bonotto, Rafaela
Nascimento Alves, Lais
Kazungu, Yvette
Poggianella, Monica
Martinez-Orellana, Pamela
Skoko, Natasa
Polez, Sulena
Marcello, Alessandro
VIRUSES-BASEL, 2021, 13 (05):
[32] Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection by a Phylogenetically Distinct Strain
Van Elslande, Jan
Vermeersch, Pieter
Vandervoort, Kris
Wawina-Bokalanga, Tony
Vanmechelen, Bert
Wollants, Elke
Laenen, Lies
Andre, Emmanuel
Van Ranst, Marc
Lagrou, Katrien
Maes, Piet
CLINICAL INFECTIOUS DISEASES, 2021, 73 (02) : 354 - 356
[33] Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
Abu-Raddad, Laith J.
Chemaitelly, Hiam
Ayoub, Houssein H.
Yassine, Hadi M.
Benslimane, Fatiha M.
Al Khatib, Hebah A.
Tang, Patrick
Hasan, Mohammad R.
Coyle, Peter
AlMukdad, Sawsan
Al Kanaani, Zaina
Al Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar Hassan
Latif, Ali Nizar
Shaik, Riyazuddin Mohammad
Abdul Rahim, Hanan F.
Nasrallah, Gheyath K.
Al Kuwari, Mohamed Ghaith
Butt, Adeel A.
Al Romaihi, Hamad Eid
Al-Thani, Mohamed H.
Al Khal, Abdullatif
Bertollini, Roberto
CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E1188 - E1191
[34] Seroprevalence of antibodies against severe acute respiratory coronavirus 2 (SARS-CoV-2) in household dogs in Japan
Ito, Genta
Goto-Koshino, Yuko
Kuroda, Yudai
Eunsil, Park
Maeda, Ken
Soma, Takehisa
Momoi, Yasuyuki
JOURNAL OF VETERINARY MEDICAL SCIENCE, 2021, 83 (11): : 1722 - 1725
[35] Comormaities and Symptomatology of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-Related Myocarditis and SARS-CoV-2 Vaccine-Related Myocarditis: A Review
Cushion, Sarah
Arboleda, Vania
Hasanain, Yousef
Beckler, Michelle Demory
Hardigan, Patrick
Kesselman, Marc M.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (04)
[36] mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months
Tande, Aaron J.
Pollock, Benjamin D.
Shah, Nilay D.
Binnicker, Matthew
Berbari, Elie F.
INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2022, 43 (03) : 393 - 395
[37] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System
De Felice, Fernanda G.
Tovar-Moll, Fernanda
Moll, Jorge
Munoz, Douglas P.
Ferreira, Sergio T.
TRENDS IN NEUROSCIENCES, 2020, 43 (06) : 355 - 357
[38] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis
Charlotte Steenblock
Vladimir Todorov
Waldemar Kanczkowski
Graeme Eisenhofer
Andreas Schedl
Ma-Li Wong
Julio Licinio
Michael Bauer
Allan H. Young
Raul R. Gainetdinov
Stefan R. Bornstein
Molecular Psychiatry, 2020, 25 : 1611 - 1617
[39] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis
Steenblock, Charlotte
Todorov, Vladimir
Kanczkowski, Waldemar
Eisenhofer, Graeme
Schedl, Andreas
Wong, Ma-Li
Licinio, Julio
Bauer, Michael
Young, Allan H.
Gainetdinov, Raul R.
Bornstein, Stefan R.
MOLECULAR PSYCHIATRY, 2020, 25 (08) : 1611 - 1617
[40] A Case of Early Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Larson, Derek
Brodniak, Sterling L.
Voegtly, Logan J.
Cer, Regina Z.
Glang, Lindsay A.
Malagon, Francisco J.
Long, Kyle A.
Potocki, Ronald
Smith, Darci R.
Lanteri, Charlotte
Burgess, Timothy
Bishop-Lilly, Kimberly A.
CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) : E2827 - E2828

← 1 2 3 4 5 →